Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?
Year of publication: |
2010
|
---|---|
Authors: | Hemphill, Thomas |
Published in: |
Journal of Business Ethics. - Springer, ISSN 0167-4544. - Vol. 94.2010, 2, p. 225-242
|
Publisher: |
Springer |
Subject: | Biotechnology Industry Organization | corporate social responsibility | extraordinary pricing | National Organization for Rare Disorders | Inc. | orphan drugs | patient access | Pharmaceutical Research and Manufacturers of America | pharmaceutical industry | pharmaceutical pricing | reputation |
-
Bruyaka, Olga, (2013)
-
Corporate Social Responsibility (CSR) of innovative pharmaceutical corporations : the case of BIOGEN
Witkowska, Janina, (2018)
-
Legislation for sale? : the influence of PhRMA campaign donations on the US house health legislation
Flaxman, Brian, (2023)
- More ...
-
An analysis of sovereign wealth funds' recent venture in developed capital markets
Jory, Surendranath R., (2008)
-
Hemphill, Thomas, (2013)
-
The Latest on Occupational Licensing Reform
Hemphill, Thomas, (2018)
- More ...